Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants

Related Experiment Video

Updated: Jun 23, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Jennifer M Stancil1, Timothy R Peters, Laurence B Givner

  • 1Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

Archives of Pediatrics & Adolescent Medicine
|May 6, 2009
PubMed

Insights

Accelerating the pneumococcal conjugate vaccine (PCV) first dose from 2 months to 6 weeks could significantly reduce invasive pneumococcal disease in infants. This strategy may prevent over 100 cases annually, offering crucial protection.

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Epidemiology

Background:

  • Invasive pneumococcal disease (IPD) poses a significant threat to infants.
  • The current pneumococcal conjugate vaccine (PCV) schedule begins the first dose at 2 months of age.
  • Early protection against pneumococcal serotypes is critical for infant health.

Purpose of the Study:

  • To estimate the impact of administering the first PCV dose earlier, at 6 weeks instead of 2 months.
  • To quantify the potential reduction in IPD burden among young infants.
  • To inform vaccination strategies for new PCV introductions.

Main Methods:

  • Utilized a prediction model based on retrospective cohort data.
  • Analyzed published data from 8 US states surveillance data prior to PCV introduction (1997-2000).
  • Modeled the effect of PCV acceleration on IPD rates in infants aged 61-90 days.

Main Results:

  • Accelerating the PCV first dose to 6 weeks could reduce IPD in infants aged 61-90 days by 39.9% to 72.1%, depending on vaccine efficacy (50%-90%).
  • This acceleration could prevent an estimated 73 to 133 IPD cases annually in the US.
  • The potential reduction is substantial, highlighting the benefit of early vaccination.

Conclusions:

  • Early administration of PCV at 6 weeks significantly reduces the burden of infant IPD.
  • This strategy is particularly relevant for new PCV formulations and populations with high IPD prevalence.
  • Optimizing PCV schedules enhances protection against severe pneumococcal infections in infants.
Abstract

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...